curacle co., ltd. Logo

curacle co., ltd.

A clinical-stage biopharma developing drugs for intractable vascular diseases.

365270 | KO

Overview

Corporate Details

ISIN(s):
KR7365270008
LEI:
Country:
South Korea
Address:
서울특별시 서초구 효령로 23-1, 서울특별시

Description

Curacle Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs for intractable vascular diseases. The company's core platform technology centers on developing highly effective protectors against endothelial dysfunction, a key factor in various age-related and vascular conditions. Its development pipeline includes novel treatments targeting significant unmet medical needs, with a particular focus on conditions such as Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (wet AMD), diabetes, and stroke. Curacle aims to create differentiated therapies through innovative targets and treatment concepts, including the development of orally administered medications for complex eye diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-12 00:00
반기보고서 (2025.06)
Korean 939.8 KB
2025-07-24 00:00
주식등의대량보유상황보고서(일반)
Korean 102.2 KB
2025-07-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.2 KB
2025-07-04 00:00
유상증자1차발행가액결정
Korean 7.9 KB
2025-07-04 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 42.6 KB
2025-07-04 00:00
[발행조건확정]증권신고서(지분증권)
Korean 243.3 KB
2025-07-04 00:00
투자설명서
Korean 1.9 MB
2025-07-04 00:00
권리락 (유상증자)
Korean 3.5 KB
2025-06-19 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 70.0 KB
2025-06-19 00:00
[기재정정]증권신고서(지분증권) (2025.08)
Korean 2.5 MB
2025-06-13 00:00
임원ㆍ주요주주특정증권등거래계획보고서
Korean 44.3 KB
2025-06-09 00:00
[기재정정]증권신고서(지분증권) (2025.07)
Korean 3.1 MB
2025-05-28 00:00
전환사채(해외전환사채포함)발행후만기전사채취득 (제1회차)
Korean 9.7 KB
2025-05-26 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-05-22 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 49.3 KB

Automate Your Workflow. Get a real-time feed of all curacle co., ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for curacle co., ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for curacle co., ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.